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Hospitalization rates 
for complications due to systemic 
therapy in the United States
Anshul Saxena1,2, Muni Rubens3, Venkataraghavan Ramamoorthy1,4, Raees Tonse1, 
Emir Veledar1,2, Peter McGranaghan3, Subrina Sundil5, Michael D. Chuong2,3, 
Matthew D. Hall2,3, Yazmin Odia2,3, Minesh P. Mehta2,3 & Rupesh Kotecha2,3* 
The aim of this study was to estimate the trends and burdens associated with systemic therapy-
related hospitalizations, using nationally representative data. National Inpatient Sample data from 
2005 to 2016 was used to identify systemic therapy-related complications using ICD-9 and ICD-10 
external causes-of-injury codes. The primary outcome was hospitalization rates, while secondary 
outcomes were cost and in-hospital mortality. Overall, there were 443,222,223 hospitalizations 
during the study period, of which 2,419,722 were due to complications of systemic therapy. The 
average annual percentage change of these hospitalizations was 8.1%, compared to − 0.5% for 
general hospitalizations. The three most common causes for hospitalization were anemia (12.8%), 
neutropenia (10.8%), and sepsis (7.8%). Hospitalization rates had the highest relative increases for 
sepsis (1.9-fold) and acute kidney injury (1.6-fold), and the highest relative decrease for dehydration 
(0.21-fold) and fever of unknown origin (0.35-fold). Complications with the highest total charges 
were anemia ($4.6 billion), neutropenia ($3.0 billion), and sepsis ($2.5 billion). The leading causes of 
in-hospital mortality associated with systemic therapy were sepsis (15.8%), pneumonia (7.6%), and 
acute kidney injury (7.0%). Promoting initiatives such as rule OP-35, improving access to and providing 
coordinated care, developing systems leading to early identification and management of symptoms, 
and expanding urgent care access, can decrease these hospitalizations and the burden they carry on 
the healthcare system.
Cancer continues to be a leading cause of morbidity and mortality, and currently an estimated 15.5 million 
cancer survivors are living in the United  States1. Cancer treatments have significantly improved survival rates 
and quality of life, leading to an increasing number of patients receiving ongoing  treatment2,3. In fact, every year 
in the United States, an estimated 650,000 patients receive systemic therapy as part of their cancer  treatment4. 
Although systemic therapies have led to improved survival rates overall, they have also been associated with 
adverse events, some of which may result in  hospitalization5,6. Many studies have described hospitalizations 
among cancer patients receiving systemic  therapy5,7–11. The majority of these studies show that complications such 
as neutropenia, thrombocytopenia, anemia, infections, fever, mucositis, dehydration, and nausea and vomiting 
are responsible for the majority of hospitalizations.
Hospitalizations due to complications of systemic therapy involve significant expenditures and can be a 
significant burden for both cancer patients and the healthcare system. A report published in 2007 by MedStat 
showed that each such hospitalization incurred an average expenditure of $22,000 per  patient12. In addition, 
hospitalizations for complications can result in treatment interruptions and adversely affect patients’ responses to 
treatment. Understanding the characteristics of these hospitalizations could help physicians and other healthcare 
providers to develop preventive strategies and manage complications in outpatient settings. To the best of our 
knowledge, there is no study that has characterized hospitalizations for complications of systemic therapy at the 
national level. Therefore, this study sought to identify the trends as well as the burdens associated with these 
hospitalizations using a nationally representative dataset.
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Methods
Data source. We used National Inpatient Sample (NIS) data from 2005 to 2016 to characterize hospitaliza-
tions for complications of systemic therapy. NIS is the largest all-payer inpatient database in the United States 
and was developed by the Agency for Healthcare Research and Quality (AHRQ) as a part of Healthcare Cost 
and Utilization Project (HCUP)13. NIS has enabled researchers and policymakers to estimate parameters such as 
healthcare utilization and outcomes, hospitalization cost, access and quality of care, and total healthcare spend-
ing at the national level, which are useful for healthcare policy decisions. Each year, the NIS collects data from 
more than 7 million hospitalizations in the United Sates, which corresponds to 35 million weighted hospitali-
zations. To increase its ability in capturing national estimates, the NIS redesigned its data collection methods 
in 2012. The NIS currently collects and stores a sample of discharge records from all hospitals participating in 
HCUP, rather than all discharge records collected from a sample of hospitals (as was its practice prior to 2012). 
Hospitalization data within the NIS contains one primary and as many as 29 secondary diagnoses, in addition to 
other variables, such as demographics, hospital data, clinical procedures, length of stay, disposition status, and 
total charges. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 
and Tenth Revision (ICD-10-CM) codes were used for reporting primary and secondary diagnoses in this study.
Study design. The current study was a retrospective analysis of NIS data collected from 2005 to 2016. Can-
cer patients were identified through Clinical Classifications Software (CCS) codes 11–45 indicating neoplasms 
as described  previously14. Cancers were categorized into solid tumors and hematologic malignancies (Table 1). 
Complications of systemic therapy were identified using ICD-9-CM and ICD-10-CM external causes-of-injury 
codes (E-codes) (Supplement File). The first listed non-cancer diagnosis identified using the ICD-9-CM or ICD-
10-CM diagnosis code as the primary reason for hospitalization (eTable S1). The procedures used for selecting 
the patient cohort are presented in the CONSORT diagram (eFig. S1). Other variables included demographics 
(age, sex, race), socioeconomic factors (median household income by zip code, insurance type), and hospital 
characteristics (region, bed size, and teaching status). Primary outcome variables included hospitalization rate 
and total cost; secondary outcome variables included hospital length of stay and in-hospital mortality for com-
plications. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
guidelines for reporting our findings. The methods for this study were conducted in accordance with relevant 
Table 1.  Hospitalizations for complications of systemic therapy by tumor type, 2005–2016 (n = 2,419,722). 
*The total number of hospitalizations for all cancers considered together is be less than the sum of the 
hospitalizations for individual cancers because some patients had multiple cancers.
Tumor type Number of hospitalizations, n (%, 95% CI)
Solid
Bladder 43,399 (1.8%, 1.6–1.8%)
Bone and connective tissue 81,465 (3.3%, 3.0–3.4%)
Brain and nervous system 40,399 (1.6%, 1.5–1.7%)
Breast 275,956 (11.1%, 10.8–11.3%)
Cervix 27,487 (1.1%, 1.0–1.2%)
Colon 144,433 (5.8%, 5.6–5.9%)
Esophagus 39,130 (1.6%, 1.5–1.8%)
Head and neck 79,670 (3.2%, 3.1–3.3%)
Kidney and renal 45,054 (1.8%, 1.7–1.9%)
Liver and intrahepatic bile duct 28,466 (1.1%, 1.1–1.2%)
Lung 362,761 (14.6%, 14.2–15.0%)
Melanoma 36,696 (1.5%, 1.3–1.6%)
Other 47,057 (1.9%, 1.7–2.0%)
Ovary 87,741 (3.5%, 3.4–3.6%)
Pancreas 73,264 (3.0%, 2.8–3.2%)
Prostate 75,842 (3.1%, 2.9–3.3%)
Rectum and anus 76,460 (3.1%, 3.0–3.2%)
Stomach 39,917 (1.6%, 1.5–1.7%)
Testis 21,050 (0.85%, 0.78–0.91%)
Thyroid 9117 (0.47%, 0.34–0.38%)
Uterus 39,406 (1.6%, 1.5–1.8%)
Liquid
Hodgkin lymphoma 40,677 (1.6%, 1.5–1.7%)
Non-Hodgkin lymphoma 334,229 (13.5%, 13.2–13.7%)
Multiple myeloma 117,879 (4.8%, 4.5–4.9%)
Leukemia 385,258 (15.5%, 15.0–16.0%)
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guidelines and regulations. We followed the Strengthening the Reporting of Observational Studies in Epidemiol-
ogy guidelines for reporting our findings.
The study was reviewed by the Miami Cancer Institute’s Institutional Review Board (IRB), which exempted 
the study from IRB approval. The IRB also waived the requirement for informed consent because it used previ-
ously collected de-identified data stored in NIS.
Statistical analysis. Statistical analyses were performed using SAS (version 9.4, SAS Institute, Cary, North 
Carolina), which accounts for the complex survey design and clustering. The guidelines for using NIS data devel-
oped by Khera and Krumholz were used to ensure appropriate procedures for the  study15. As already mentioned, 
the NIS was redesigned in 2012 to improve national estimates. To account for these changes, we used modified 
discharge weights for the years 2005–201116. Descriptive statistics were used to understand temporal factors, 
types of cancers, demographics, socioeconomic factors, and hospital characteristics. Hospitalization rates were 
calculated by dividing the total number of patients hospitalized due to complications of systemic therapy by the 
total number of hospitalizations. Costs of individual inpatient-stays were calculated by multiplying total hospital 
charges by cost-to-charge ratios. The costs for each year were adjusted according to 2016 inflation levels, based 
on the US Consumer Price Index. Hospital length of stay was estimated by subtracting the admission date from 
the discharge date. In-hospital mortality was calculated by dividing the number of patients admitted for compli-
cations of systemic therapy and those who died in the hospital by the total number of patients hospitalized due to 
complications of systemic therapy. All analyses included weighted frequencies for calculating national estimates. 
Statistical significance was set at P < 0.05.
Conference presentation. This study was presented at the ASCO Annual Meeting from May 29–31, 2020.
Results
There were 443,222,223 weighted hospitalizations recorded during the period 2005–2016, of which 2,419,722 were 
due to complications of systemic therapy. The majority of patients (55.3%, 95% CI 44.2–45.7%) were ≥ 60 years 
old and female (52.5%, 95% CI 51.3–51.8%) (eTable S2). The majority of the patients were White (66.2%, 95% 
CI 65.8–67.9%), followed by Blacks (9.5%, 95% CI 9.1–9.8%), and Hispanics (8.7%, 95% CI 7.7–8.9%). Nearly 
65.2% (95% CI 63.7–66.6%) of the patients were admitted in hospitals with large bed capacity, and 63.8% (95% 
CI 61.2–64.3%) were admitted to urban teaching hospitals. Region-wide distribution showed that the majority 
of the patients were admitted in the South (36.7%, 95% CI 35.1–38.4%), followed by the Midwest (24.0%, 95% 
CI 22.4–25.4%), the West (21.1%, 95% CI 19.3–22.0%) and the Northeast (18.2%, 95% CI 17.2–19.9%). About 
4.6% (95% CI 4.3–4.7%) of the patients died during hospitalization for complications of systemic therapy. Dur-
ing the study period, the average annual percentage change (AAPC) in hospitalization rates for complications 
of systemic therapy was 8.1% (95% CI 7.3–9.1%), compared to − 0.53% (95% CI − 1.1% to − 0.21%) for general 
hospitalizations.
During the study period, hospitalizations for complications of systemic therapy had the highest relative 
increase for sepsis (1.9-fold) and acute kidney injury (1.6-fold), and the lowest relative increase for dehydration 
(0.21 fold) and fever of unknown origin (0.35-fold) (Fig. 1).
Table 2 shows the top 10 complications associated with systemic therapy in terms of the number of hospitaliza-
tions, hospital length of stay, in-hospital mortality, and charges. The 3 most common reasons for hospitalizations 
were anemia (12.8%, 95% CI 9.7–13.1%), neutropenia (10.8%, 95% CI 7.9–11.0%), and sepsis (7.8%, 95% CI 
6.0–8.1%). The length of stay was highest for sepsis (median, 6.1 days, 3.4–11.5), pneumonia (5.5 days, 3.1–10.4), 
and acute kidney injury (5.2 days, 2.8–10.2). The leading causes of in-hospital mortality included sepsis (15.8%, 
15.4–17.9%), pneumonia (7.6%, 95% CI 7.1–10.6%), and acute kidney injury (7.0%, 95% CI 6.6–10.2%). Costli-
est complications were sepsis (median, $16,834, 95% CI $16,361-$17,307), acute kidney injury ($13,172, 95% 
CI $12,381-$13,963), and pneumonia ($13,040, 95% CI $12,541-$13,538).
Subsequently, complications of systemic therapy were analyzed by cancer type, and the most common can-
cers were leukemia (15.5%, 95% CI 13.6–16.1%), lung cancer (14.6%, 95% CI 13.1–15.9%), and non-Hodgkin 
lymphoma (13.5%, 95% CI 12.2–16.1%). The most common complications of systemic therapy among solid 
tumors were neutropenia (9.4%, 95% CI 8.5–10.8%), anemia (9.2%, 95% CI 7.2–11.4%), and sepsis (7.3%, 95% 
CI 6.3–9.9%), and among hematologic malignancies were anemia (19.7%, 95% CI 17.6–21.3%), neutropenia 
(13.4%, 95% CI 11.2–15.9%), and sepsis (8.8%, 95% CI 6.5–10.5%). Although anemia, neutropenia, and sepsis 
were among the top 3 complications of systemic therapy in the majority of cancer types, exceptions included 
bone and connective tissue cancers, where nausea and vomiting were among the top 3 complications, and colon 
and head and neck cancers, where dehydration was among the top 3 complications (Fig. 2). Non-Hodgkin 
lymphoma (13.1%, 95% CI 10.4–16.2%) and leukemia (10.4%, 95% CI 8.1–12.7%) were the most common 
malignant neoplasms among patients with acute kidney injury, and breast cancer (22.1%, 95% CI 19.9–24.5%) 
and non-Hodgkin lymphoma (20.3%, 95% CI 18.5–23.1%) were the most common malignant neoplasms among 
patients with congestive heart failure.
Discussion
To the best of our knowledge, this is the first study that reports on hospitalizations for complications of systemic 
therapy, using a nationally representative dataset. In this study, hospitalizations for complications of systemic 
therapy increased significantly, in contrast to a decrease in general hospitalizations for all causes during the same 
study period. A significant majority of these hospitalizations consisted of older adults greater than 60 years of age 
on Medicare benefits and admitted to urban teaching centers. Complications associated with systemic therapy 
that resulted in the highest number of hospitalizations were anemia, neutropenia, and sepsis.
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Figure 1.  Relative change in the number of hospitalizations for neutropenia, sepsis, pancytopenia, urinary tract 
infection, dehydration, anemia, pneumonia, acute kidney injury nausea and vomiting, and fever of unknown 
origin from 2005 to 2016.
Table 2.  Number of hospitalizations, hospital length of stay, in-hospital mortality, and charges for the top 10 
complications of systemic therapy, 2005–2016 (n = 2,419,722).
Diagnosis
Number of hospitalizations 
(%, 95% CI)
Length of stay in days, 
median (IQR) Mortality, % (95% CI)
Median Charges per 
Hospitalization (95% CI)
Total Charges in Billions 
(95% CI)
Anemia 309,724 (12.8%, 9.7–13.1%) 4.9 (2.4–14.6) 2.8% (2.6–3.4%) $12,024 ($11,373–$12,674) $4.62 ($4.11–$5.12)
Neutropenia 261,330 (10.8%, 7.9–11.0%) 3.9 (2.3–6.5) 1.6% (1.4–2.8%) $9091 ($8804–$9377) $2.49 ($2.24–$2.74)
Sepsis 188,738 (7.8%, 6.0–8.1%) 6.1 (3.4–11.5) 15.8% (15.4–17.9%) $16,834 ($16,361–$17,307) $3.01 ($2.78–$3.22)
Pneumonia 106,468 (4.4%, 3.4–4.8%) 5.5 (3.1–10.4) 7.6% (7.1–10.6%) $13,040 ($12,541–$13,538) $1.65 ($1.49–$1.82)
Acute kidney injury 87,110 (3.6%, 2.8–3.7%) 5.2 (2.8–10.2) 7.0% (6.6–10.2%) $13,172 ($12,381–$13,963) $1.34 ($1.17–$1.51)
Nausea with vomiting 77,431 (3.2%, 2.3–3.3%) 2.6 (1.4–4.4) 0.70% (0.55–1.1%) $6059 ($5856–$6261) $0.43 ($0.40–$0.47)
Dehydration 72,592 (3.0%, 2.0–3.4%) 3.0 (1.6–5.5) 2.8% (2.5–3.6%) $6351 ($6159–$6543) $0.51 ($0.47–$0.55)
Urinary tract infection 31,459 (1.3%, 0.93–1.4%) 3.6 (2.1–6.2) 1.5% (1.1–4.4%) $8460 ($8135–$8784) $0.29 ($0.26–$0.32)
Congestive heart failure 31,456 (1.3%, 0.87–1.5%) 4.0 (2.3–7.1) 4.1% (3.6–5.1%) $10,120 ($9701–$10,537) $0.32 ($0.29–$0.35)
Fever of unknown origin 26,617 (1.1%, 0.71–1.2%) 2.4 (1.4–4.2) 0.33% (0.18–1.1%) $6236 ($5920–$6552) $0.18 ($0.15–$0.21)
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The observed increase in hospitalizations for complications of systemic therapy could be explained by an 
increase in the number of elderly patients who are becoming eligible for systemic  therapy1. As newer targeted 
treatments have significantly improved overall survival and progression-free survival rates in the overall popula-
tion, these benefits have also been translated to elderly patients as  well17,18. Nevertheless, these new agents have 
also increased the number of adverse events because of side effects, in addition to those already resulting from 
existing treatment  regimens19. These factors could be responsible for increasing the volume of hospitalization 
for managing these conditions. The majority of the patients were admitted in large urban teaching hospitals as 
cancer management requires intensive treatment and follow-up most widely available in higher-tiered  hospitals20.
Among patients receiving systemic therapy for both solid tumors and hematologic malignancies, anemia, 
neutropenia, and sepsis were the most common complications requiring hospitalization. This could be attrib-
uted to profound myelosuppression and immunosuppression associated with chemotherapy and bone marrow 
transplantation. In addition, bone marrow transplant recipients are more likely to experience readmissions for 
infections and graft failures in the initial month after discharge from a primary  hospitalization21. Nausea and 
vomiting were common among patients receiving systemic therapy for bone and connective tissue cancers. These 
cancers are treated with consecutive-day regimens of multiple anti-cancer drugs, resulting in higher levels of 
nausea and vomiting prominent in cisplatin-containing  regimens22. Dehydration was common among colon 
and head and neck cancers. This could be due to complications such as mucositis, common in these patients, 
limiting their ability to consume food and beverages, as well as destruction of the lining of the gastrointestinal 
tract, limiting the absorption of fluids and  electrolytes23. Acute kidney injury was common among Non-Hodgkin 
lymphoma and leukemia patients. Kidney injury in these conditions could be caused by the malignancy itself 
or as a side effect of systemic  therapy24. Congestive heart failure was common among non-Hodgkin lymphoma 
and breast cancer patients. This finding could be due to the adverse effects of medications such as trastuzumab 
and anthracycline, commonly recommended for these  cancers25.
In our study, sepsis, pneumonia, and aspiration pneumonitis were associated with prolonged length of stay 
and mortality among those receiving systemic therapy. This is not surprising as cancer treatments cause signifi-
cant immunosuppression and disruption of mucosal barriers. Some studies have reported a significant increase 
in the length of stay and higher mortality rates when cancer was complicated by severe  sepsis26,27. Pneumonia 
and aspiration pneumonitis are usually severe in leukemia and lung cancer patients and hence associated with 
greater length of stay and  mortality28,29.
The complications that were associated with the highest total charges were anemia, sepsis, neutropenia, and 
pneumonia. Though sepsis had the highest median cost, total charges were highest for anemia because of the 
large volume of patients admitted for this condition. Previous studies evaluating the financial burdens of cancer 
hospitalization have shown similar findings. For example, in a large-scale study among breast cancer patients, 
anemia and neutropenia had the highest  expenditures30. Similarly, in a retrospective study among 412,005 cancer 
patients of all types, sepsis was among the 3 most costly  complications29.
Hospitalizations for complications of systemic therapy involve significant financial burdens in addition to 
poor quality of  life29. Efforts to lower these expenditures could enormously decrease healthcare costs. An impor-
tant step in this direction would be to accurately identify unplanned hospitalizations in cancer care. Rule OP-35, 
proposed by the Centers for Medicare and Medicaid Services (CMS), offers hope in this  direction31. This rule 
proposes to identify patients who have received systemic therapy in outpatient settings and subsequently hospital-
ized for 10 major complications such as anemia, neutropenia, sepsis, pneumonia, nausea, vomiting, dehydration, 
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Figure 2.  The most common complications of systemic therapy by the top 10 most common cancer types.
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subsequently analyzed and improved with a focus on decreasing the number of unplanned hospitalizations. In 
addition to these measures, other strategies such as improving access to and providing coordinated care, develop-
ing standardized procedures for prompt identification and management of symptoms, and implementing urgent 
cancer care strategies, can significantly decrease not only hospitalization rates but also the duration of stay and 
the severity of these  complications32.
Limitations. In our study, we used E codes to identify patients who experienced hospitalizations for com-
plications of systemic therapy. However, since the NIS is primarily an administrative database, E codes could 
be underrepresented because they are not obligatory for reimbursements. This may have resulted in an under-
estimation of the volume of hospitalizations for these conditions. Furthermore, the NIS does not have data on 
tumor staging or anti-cancer medications. Therefore, we could not stratify the complications based on disease 
severity or treatment regimen, thus limiting our findings. In addition, NIS erases all personal identifiers for data 
confidentiality. Thus, the same patient readmitted multiple times would have been considered as an independent 
new admission, leading to an overestimation of hospitalization rates. Despite these limitations, we decided to 
use NIS because data on hospitalization for complications of cancer treatment is sparse. In addition, we could 
accurately calculate national estimates due to the large sample size provided by the NIS, which is the largest, all 
payer in-patient database in the United States.
Conclusions
The management of complications of cancer treatment pose a significant burden to hospitals. From 2005 to 
2016, hospitalization rates for complications of systemic therapy increased by an annual rate of 8.1%, which is 
concerning, when compared to the fact that the overall hospitalization rate decreased by an annual rate of 0.5% 
during the same period. The most common complications of systemic therapy that required hospitalization were 
anemia, neutropenia, and sepsis. Among all complications, sepsis was associated with greatest length of stay, 
highest mortality, and highest expenditures. Improved strategies for identifying and managing these complica-
tions in the outpatient and emergency settings could significantly decrease these hospitalizations, the burden on 
the healthcare system, and subsequently improve the quality of life of cancer patients.
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